While treatment of adults with CKD and T2D should be holistic, SGLT2is should be prioritised as foundational therapy, independent of BMI, to reduce cardiorenal risk. Combination therapy with GLP-1 RAs was preferred for those with ongoing CKD progression and/or high cardiometabolic risk. Further clarity is required around the optimal timing of combination and sequential add-on therapy initiation.

Type 2 diabetes mellitus requires individualized treatment strategies that account for patient-specific factors beyond population-level clinical trial outcomes. SGLT2 inhibitors and GLP-1 receptor agonists have emerged as preferred therapeutic options, offering benefits in glycemic control, cardiovascular health, renal function, and weight reduction. SGLT2 inhibitors function by inhibiting sodium-glucose transport in the kidney's proximal tubule, promoting natriuresis and osmotic diuresis that reduce plasma volume and glomerular filtration pressure, thereby lowering all-cause mortality and heart failure hospitalization risk. GLP-1 receptor agonists mimic endogenous GLP-1 hormone actions across multiple tissues including the pancreas, heart, and gastrointestinal tract. Primary care practitioners play a crucial role in optimizing outcomes by evaluating underlying disease mechanisms, treatment efficacy, medication safety profiles, and individual patient characteristics to select the most appropriate therapy.

Incretin-based therapies represent a promising pharmacological approach for obesity treatment. These medications work by enhancing the body's natural incretin hormones, which regulate blood glucose levels and promote satiety. By targeting incretin pathways, these therapies offer dual benefits: improved metabolic control and reduced appetite, leading to significant weight loss. This treatment modality demonstrates particular efficacy in patients with concurrent glucose dysregulation or type 2 diabetes. The article examines the mechanisms, clinical efficacy, and therapeutic potential of incretin-based interventions in obesity management, providing comprehensive insights into their role as an emerging therapeutic strategy for addressing this growing public health concern.

This clinical evidence review examines muscle loss and body composition changes associated with GLP-1 medications like semaglutide, tirzepatide, and liraglutide for weight management. The widely cited STEP-1 trial reported that approximately 38-39% of weight loss comprised lean mass, raising concerns about muscle preservation. However, the review clarifies that dual-energy X-ray absorptiometry scans measure "lean soft tissue," which includes not only skeletal muscle but also water, glycogen, organs, and connective tissue. Given the test's precision limitations and the simultaneous shifts in multiple tissue compartments during rapid weight loss, this percentage may overestimate actual muscle loss. The analysis provides critical context for interpreting body composition data in GLP-1 trials and evaluating the true impact on physical function and muscular health.

Amycretin is a novel unimolecular co-agonist that synergistically activates GLP-1 and amylin receptors. Dual agonism engages hindbrain satiety and delays gastric emptying to overcome efficacy ceilings of current monotherapies. Oral amycretin achieves 13.1% weight loss at 12 weeks, surpassing existing oral agents. Subcutaneous administration yields 24.3% weight loss in 36 weeks with rapid onset.

Before age 50, the body has considerable metabolic resilience. After 50, several things shift simultaneously. Visceral fat accumulation increases, even without major weight gain. Arterial stiffness progresses. The kidneys begin to lose some filtering capacity. The heart’s electrical system becomes more vulnerable to rhythm disturbances. And chronic low-grade inflammation — driven partly by excess fat tissue and partly by the aging process itself — begins to accelerate damage across multiple organ systems.Obesity does not cause cardiovascular disease in isolation, but it intensifies nearly every risk factor: high blood pressure, insulin resistance, abnormal cholesterol, systemic inflammation, and sleep apnea all worsen with excess weight. Treating obesity, therefore, is not cosmetic medicine — it is preventive cardiology.

North American hospitality and foodservice operators face rapidly evolving menu demands driven by GLP-1 medication influences, functional beverages, and consumer preference for authentic global cuisine. A comprehensive F&B Trends Guide identifies twelve key trends shaping 2026-2027, offering practical strategies to enhance margins and competitiveness. The most significant shift concerns customers' fundamental relationship with mealtimes themselves, with beverage offerings gaining equal importance to cuisine. Success increasingly depends on deeper ingredient sourcing and culinary craft rather than constant innovation. The guide provides chef-developed recipes and actionable guidance, emphasizing that most trends require strategic thinking about existing menus and supplier relationships rather than substantial capital investment.

This document outlines comprehensive pharmacy management drug policies designed to establish standardized protocols for pharmaceutical operations and controlled substance handling. The policy framework addresses critical aspects including inventory management, dispensing procedures, staff responsibilities, and compliance with regulatory requirements. It serves as an essential reference guide for pharmacy personnel to maintain operational efficiency, ensure patient safety, and uphold legal and ethical standards in drug distribution and administration. The document provides structured guidance on implementing best practices while minimizing risks associated with pharmaceutical management in healthcare settings.

Recent clinical trials demonstrate that GLP-1 receptor agonists offer significant cardiovascular protection beyond weight reduction, particularly for individuals over 50. The SELECT trial, published in November 2023, enrolled over 17,000 non-diabetic adults with existing cardiovascular disease and elevated BMI, revealing that semaglutide substantially reduced major cardiovascular events. After age 50, metabolic changes including increased visceral fat, arterial stiffness, and chronic inflammation amplify cardiovascular risk. GLP-1 medications directly protect the heart, kidneys, and blood vessels through mechanisms independent of weight loss alone, making them valuable preventive cardiology tools for managing obesity and reducing disease progression in older populations at elevated cardiovascular risk.

Limited-time offerings (LTOs) have become a strategic growth driver for the restaurant industry, driven by three primary consumer motivations. Health-conscious diners increasingly seek nutritious menu innovations, while novelty appeals to customers seeking fresh dining experiences and social media engagement opportunities. Value-oriented promotions attract price-sensitive consumers navigating economic pressures. This convergence of health, innovation, and affordability positions LTOs as powerful tools for enhancing customer traffic, generating excitement, and maintaining competitive differentiation. Restaurants leveraging these temporary offerings effectively can drive revenue growth, test new concepts with manageable risk, and respond agilely to evolving consumer preferences in an increasingly competitive market landscape.

GLP-1 receptor agonists, including semaglutide and tirzepatide marketed as Ozempic and Wegovy, have emerged as breakthrough medications extending far beyond their original weight loss applications. Recent research demonstrates therapeutic potential across multiple conditions, including cancer, cardiovascular disease, diabetes, depression, anxiety, endometriosis, and Parkinson's disease. This drug repurposing initiative represents a significant shift in pharmaceutical development, as scientists explore previously unrecognized benefits of these compounds. The findings suggest GLP-1 drugs may address numerous chronic health conditions simultaneously, potentially transforming treatment paradigms across multiple medical specialties and improving patient outcomes significantly.

Portions plus petites, protéines en extra… Les médicaments pour la perte de poids étant de plus en plus répandus, les restaurants américains modifient leur offre pour répondre aux besoins de leurs clients.

SGLT2 inhibitors and GLP-1 receptor agonists have emerged as preferred treatment options for Type II diabetes mellitus, offering significant benefits beyond glycemic control, including cardiovascular protection, renal outcomes improvement, and weight reduction. Primary care practitioners play a vital role in optimizing clinical outcomes by selecting therapies based on individual patient characteristics rather than population-level trial data. SGLT2 inhibitors reduce all-cause and cardiovascular mortality while decreasing heart failure hospitalization risk through mechanisms involving sodium-glucose transport inhibition in the kidney, promoting natriuresis and osmotic diuresis. Individualized treatment approaches considering underlying disease mechanisms, medication efficacy, safety profiles, and patient-specific factors are essential for effective diabetes management.

GLP-1 receptor agonists, including semaglutide and liraglutide, represent a significant advancement in both diabetes management and kidney disease prevention. These medications offer direct renal protection beyond traditional glucose control, slowing chronic kidney disease progression by twenty to thirty percent in clinical trials. GLP-1s work through synthetic incretin hormones that regulate blood sugar while simultaneously protecting kidney cells through direct receptor activation in renal tissue. While most kidney-related side effects remain mild and temporary, primarily affecting hydration through nausea, the benefits substantially outweigh risks for diabetic patients. This dual metabolic and renal approach addresses diabetic nephropathy, which affects nearly forty percent of diabetic individuals, providing a promising new treatment paradigm for kidney health protection.

Recent research demonstrates that glucagon-like peptide-1 receptor agonists significantly reduce cardiovascular and renal risks in type 1 diabetes patients. A large-scale study analyzing data from 174,678 patients found that GLP-1 treatment reduced the 5-year risk of major adverse cardiovascular events by 15% and end-stage kidney disease by 19%, without introducing new safety concerns. These protective effects mirror outcomes observed in type 2 diabetes populations. The findings, derived from electronic health records using propensity score analysis, suggest GLP-1 drugs may offer comparable cardiorenal benefits across diabetes types, potentially expanding treatment options for type 1 diabetes management.

Recent clinical evidence reviews examine muscle loss during GLP-1 receptor agonist therapy for weight management. The landmark STEP-1 trial with semaglutide reported that approximately 38-39 percent of total weight loss comprised lean mass according to dual-energy X-ray absorptiometry (DXA) scans. However, this figure warrants careful interpretation, as DXA scans measure lean soft tissue rather than skeletal muscle exclusively. The category includes water, glycogen, organ tissue, connective tissue, and intramuscular fat, which DXA cannot differentiate. Understanding these measurement limitations is essential for clinicians and patients evaluating the true impact of GLP-1 medications like Ozempic, Wegovy, and Mounjaro on body composition and physical function during weight loss treatment.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

GLP-1 receptor agonists represent an emerging therapeutic approach in stroke prevention, addressing a critical gap in cardiovascular risk management. This narrative review examines the mechanisms by which GLP-1 agonists may reduce stroke incidence through multiple pathways, including improved glycemic control, weight reduction, and enhanced vascular function. The authors synthesize current evidence regarding the efficacy and safety profile of these agents in high-risk populations. As stroke remains a leading cause of morbidity and mortality globally, identifying novel preventive strategies is essential. This review highlights the promising potential of GLP-1 receptor agonists as adjunctive therapy and discusses implications for clinical practice and future research directions in cerebrovascular disease prevention.

Recent comprehensive analysis of over 90,000 patients across eleven clinical trials reveals that GLP-1 medications reduce the risk of major cardiovascular events by approximately thirteen percent over nearly three years. These drugs, widely recognized for facilitating weight loss, demonstrate substantial cardioprotective benefits extending beyond blood sugar and weight management. The study, published in Cardiovascular Diabetology–Endocrinology Reports, examined long-term outcomes in high-risk populations including individuals with type 2 diabetes, obesity, and existing heart conditions. GLP-1 receptor agonists appear to protect cardiovascular health through multiple mechanisms, including inflammation reduction, improved blood vessel function, and mitigation of key risk factors. This represents the most comprehensive review to date of long-term cardiovascular outcomes associated with these medications when used for prolonged periods exceeding one year.

A University of Virginia-led study presented at Heart Rhythm 2026 reveals that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce atrial fibrillation risk independently of weight loss. The retrospective analysis examined 13,034 patients who initiated GLP-1 RA therapy between 2020 and 2024, compared against a propensity score-matched control group of over 385,000 individuals never receiving the medication. Results demonstrated that GLP-1 RA users experienced significantly better survival rates and substantially lower atrial fibrillation risk, with benefits persisting regardless of weight change. These findings suggest GLP-1 RAs offer direct cardiovascular rhythm benefits beyond their established weight reduction effects, potentially providing important therapeutic advantages for patients at risk of atrial fibrillation.